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using human papillomavirus testing, and the negative
implications for women of increased lifetime colpo-
scopies (64-138%).
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Effect of testing for human papillomavirus as a triage
during screening for cervical cancer: observational before
and after study
Sue Moss, Alastair Gray, Rosa Legood, Martin Vessey, Julietta Patnick, Henry Kitchener on behalf of
the Liquid Based Cytology/Human Papillomavirus Cervical Pilot Studies Group
Abstract
Objective To assess the effect of introducing testing
for human papillomavirus combined with liquid
based cytology in women with low grade cytological
abnormalities.
Design Observational before and after study.
Setting Three cervical screening laboratories,
England.
Participants 5654 women aged 20-64 with low grade
cytological abnormalities found at routine cervical
screening in a pilot; 5254 similar women in the period
before the pilot.
Interventions Human papillomavirus testing
combined with liquid based cytology in the
management of women with borderline or mildly
dyskaryotic cervical smear results compared with
conventional smear tests, with immediate referral to
colposcopy of women positive for human
papillomavirus.
Results 57.9% (3187/5506) of women tested in the
pilot were positive for human papillomavirus. The
rate of repeat smears fell by 74%, but the rate of
referral to colposcopy for low grade cytological
abnormalities more than doubled. The estimated
negative predictive value of human papillomavirus
testing varied between 93.8% and 99.7%.
Conclusion The addition of testing for human
papillomavirus in women with low grade cytological
abnormalities resulted in a reduction in the rate of
repeat smears, but an increase in rates of referral to
colposcopy.
Members of the pilot studies group are on bmj.com
This article was posted on bmj.com on 6 January 2006: http://bmj.com/
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Introduction
Oncogenic human papillomavirus has been detected
in almost all invasive cancers; its prevalence in precan-
cerous lesions varies from about 80% to 95%. Triaging
women with low grade cytological abnormalities on
the basis of their human papillomavirus status would
reduce requirements for repeat cytology and could
improve utilisation of colposcopy1; the introduction of
liquid based cytology increases the feasibility of DNA
testing for human papillomavirus.
Methods
The Department of Health commissioned pilot studies
in which three cytopathology laboratories in England
converted to using liquid based cytology combined
with testing for human papillomavirus of women with
borderline or mildly dyskaryotic cervical smear results
for a 12 month period.
Results
A total of 5654 women aged 20-64 in the NHS cervical
screening programme had borderline (n = 3797) or
mildly dyskaryotic (n = 1857) smear results; 45.6%
(1680/3681) and 82.6% (1507/1825) of those women
tested, respectively, were positive for human papilloma-
virus. Respective results by age groups were 64.4%
(1239) and 89.0% (1188) for women aged 20-34 years,
29.0% (353) and 69.4% (259) for those aged 35-49
years, and 16.2% (88) and 51.3% (60) for those aged
50-64 years.
Women who tested positive for human papilloma-
virus were referred for immediate colposcopy. Women
who tested negative were referred for colposcopy if at
six months cytology showed mild dyskaryosis or worse
or they tested positive for human papillomavirus. As
the protocol led to increased referral for colposcopy,
two centres revised the protocol after six and eight
months and referred younger women (20-34 years)
positive for the virus only if at six months they
remained positive or cytology showed mild dyskaryosis
or worse. At six months, 64% (253/396) remained
positive and 73.5% met the criteria for referral.
For comparison we collected data on 5245 women
of a similar age distribution with borderline or mildly
dyskaryotic smear results in the 12 months before
the pilot, when policy would have been to refer for
colposcopy only after, respectively, two or one further
abnormal smear results.
Estimated default rates for repeat smears for
women negative for human papillomavirus were
19.4% (403/2075) compared with 15.7% for women
with low grade abnormalities in the period before the
pilot, whereas the estimated default rate for colposcopy
in women positive for human papillomavirus and
referred directly was 11.2% (264/2358).
In the initial protocol period the rate of repeat
smears per woman fell by 70% for borderline smear
results from 1.40 to 0.42 (rate ratio 0.30, 95%
confidence interval 0.28 to 0.32) and by 87% for mildly
dyskaryotic smear results, from 1.18 to 0.15 (0.13, 0.11
to 0.15). The rates of referral for colposcopy for these
two categories increased from 15% to 44% (2.92, 2.64
to 3.24) and from 37% to 80% (2.15, 1.93 to 2.40),
respectively (table).
Assuming that no high grade disease is present in
those women who remained negative for human pap-
illomavirus at six months (or were not retested) and
were not referred for colposcopy, the negative
predictive value of the human papillomavirus test for
cervical intraepithelial neoplasia grade 2 or worse was
estimated as 99.4% for women with borderline smear
results and 96.5% for those with mildly dyskaryotic
smear results.
Discussion
Although rates of repeat smears were reduced after
triaging women on the basis of their human
papillomavirus status, colposcopy referral rates were
increased. Rates of referral to colposcopy after a
borderline smear result may have been underestimated
for the period before the pilot period. One study
reported long term colposcopy and biopsy rates of
42% in a similar group of women.2
The estimated negative predictive value of testing
for human papillomavirus was high and in line with
other studies.3 Detection of cervical intraepithelial neo-
plasia (CIN) grades 2 and 3 increased during the initial
protocol period, although this may simply represent
more efficient diagnosis of prevalent disease. With the
lower screening threshold raised to the age of 25, triage
on the basis of human papillomavirus testing for
borderline smear results may detect an increased
amount of prevalent CIN-2 and CIN-3.
Results from other studies have been used to
suggest different strategies for human papillomavirus
testing or triage.4 5 The significant increase in referral
rates for colposcopy observed in the present study
means that if triage on the basis of human papilloma-
virus testing is to be implemented, appropriate
management strategies need to be developed and
introduced in a controlled manner.
This study forms part of the independent evaluation of the
liquid based cytology/human papillomavirus cervical screening
pilot studies commissioned by the Policy Research Programme
at the Department of Health. The evaluation was carried out by
research teams at the Cancer Screening Evaluation Unit,
Institute of Cancer Research (SM, E Henstock), the Health Eco-
nomics Research Centre, University of Oxford (AG,RL), and the
Psychology and Genetics Research Group, King’s College Lon-
don (T Marteau, E Maissi). The views expressed are those of the
authors and not necessarily those of the Department of Health.
Rates of repeat smears and referral to colposcopy for women with borderline or mildly
dyskaryotic smear results according to age group
Smear
results
(age
group)
Rate of repeat smears per woman Rate of referral to colposcopy (%)
Before
pilot Pilot
Before
pilot Pilot
Initial
protocol
period
Revised
protocol
period
Both
periods*
Initial
protocol
period
Revised
protocol
period
Both
periods*
Borderline:
20-34 1.28 0.26 0.71 — 19 59 32 —
35-64 1.50 0.61 0.62 0.61 12 27 26 27
Total 1.40 0.42 0.67 15 44 29
Mildly
dyskaryotic
20-34 1.11 0.08 0.72 — 39 82 52 —
35-64 1.35 0.35 0.18 0.30 34 73 78 75
Total 1.18 0.15 0.55 37 80 60
*For age group 35-64 when protocol remained unchanged.
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Risk factors for pulmonary tuberculosis in Russia:
case-control study
Richard Coker, Martin McKee, Rifat Atun, Boika Dimitrova, Ekaterina Dodonova, Sergei Kuznetsov,
Francis Drobniewski
Abstract
Objectives To determine risk factors for pulmonary
tuberculosis in Russia.
Design Case-control study of exposure to a variety of
risk factors before and during the development of
pulmonary tuberculosis.
Setting Large city in Russia.
Participants Cases were 334 consecutive adults
diagnosed as having culture confirmed pulmonary
tuberculosis between 1 January 2003 and
31 December 2003. Controls were 334 individuals
sampled from a validated population registry,
matched for age and sex to the patients with
tuberculosis. A questionnaire collected information
on potential risk factors.
Main outcome measures Risk factors associated with
the development of tuberculosis.
Results The main risk factors for tuberculosis were
low accumulated wealth (univariate odds ratio 16.70),
financial insecurity (5.67), consumption of
unpasteurised milk (3.58), diabetes (2.66), living with
a relative with tuberculosis (2.94), being unemployed
(6.10), living in overcrowded conditions (2.99), illicit
drug use (8.74), and a history of incarceration in both
pretrial detention centres (5.70) and prison (12.50).
Conclusions When prevalence of exposure is taken
into account the most important factors in the
development of pulmonary tuberculosis in Russia are
exposure to raw milk and unemployment.
Introduction
Rates of tuberculosis in Russia have increased since the
break-up of the Soviet Union, but little is known about
the risk factors for developing the disease. This
case-control study aimed to determine the risk factors
for pulmonary tuberculosis in adults in a region of
Russia where changes in rates of tuberculosis have
mirrored those for the country as a whole.
Methods
We undertook a case-control study in the city of
Samara, 700 miles southeast of Moscow. All partici-
pants were residents of the city. We defined cases as all
adults with culture confirmed pulmonary tuberculosis
newly diagnosed at any of the city’s specialist
tuberculosis clinics between 1 January 2003 and
31 December 2003, and recruited to a WHO DOTS
(directly observed treatment short course) programme.
We estimated that 307 cases and an equal number of
controls should be recruited to achieve 80% power to
detect an odds ratio of 2.0 at the 5% significance level if
10% or more of the general population were exposed
to the risk factor. Controls were sampled randomly
from the general population of Samara city; they were
matched for year of birth and sex, and they had no his-
tory of tuberculosis. A team of 22 trained interviewers
administered a previously piloted questionnaire to
What is already known on this topic
Testing for human papillomavirus could improve
the management of women with borderline or
mildly dyskaryotic smear results
Human papillomavirus testing for borderline
cytology and colposcopy for women positive for
human papillomavirus has greater sensitivity to
detect cervical intraepithelial neoplasia grades 2
and 3 than repeat cytology
What this study adds
Triaging women on the basis of testing for human
papillomavirus is feasible during cervical
screening
Such testing in pilot studies in England led to
reduced rates of repeat smears but increased
referrals for colposcopy
This article was posted on bmj.com on 8 December 2005:
http://bmj.com/cgi/doi/10.1136/bmj.38684.687940.80
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